A single dose of killed Mycobacterium bovis BCG in a novel class of adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis

Vaccine

Volumn 22, Issue 8, 2004, Pages 1063-1071

  Chambers, Mark A ^a   Wright, D Craig ^b   Brisker, Joan ^b   Williams, Ann ^c   Hatch, Graham ^c   Gavier Widén, Dolores ^a,d   Hall, Graham ^c   Marsh, Philip D ^c   Hewinson, R Glyn ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b NOVAVAX INC   (United States)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

Liposome; M. bovis; Vaccine

Indexed keywords

BCG VACCINE; FORMALDEHYDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; NOVASOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; IMMUNE DEFICIENCY; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TUBERCULOSIS; VACCINATION;

EID: 1242270634     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.05.002     Document Type: Article

References (57)

1. Grange J.M., Collins C.H. Bovine tubercle bacilli and disease in animals and man. Epidemiol. Infect. 99:1987;221-234.
2. Salo W.L., Aufderheide A.C., Buikstra J., Holcomb T.A. Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2091-2094.
3. Crubezy E., Ludes B., Poveda J.D., Clayton J., Crouau-Roy B., Montagnon D. Identification of Mycobacterium DNA in an Egyptian Pott's disease of 5400 years old. C. R. Acad. Sci. III. 321:1998;941-951.
4. Dankner W.M., Waecker N.J., Essey M.A., Moser K., Thompson M., Davis C.E. Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine (Baltimore). 72:1993;11-37.
5. O'Reilly L.M., Daborn C.J. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuberc. Lung Dis. 76(Suppl. 1):1995;1-46.
6. Steele JH. Regional and country status reports - introduction. In: Thoen CO, Steele JH, editors. Mycobacterium bovis infection in animals and humans. Ames, IA: University Press; 1995. p. 47-61.
7. Krebs JR. Bovine tuberculosis in cattle and badgers. London, UK: Ministry of Agriculture, Fisheries and Food Publications, London; 1997.
8. Bloom BR, Fine PEM. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenicity, protection, and control. Washington: American Society for Microbiology; 1994. p. 531-57.
9. Hart P.D., Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br. Med. J. 2:1977;293-295.
10. Anonymous. Trial of BCG vaccines in South India for tuberculosis prevention. Indian J Med Res 198072 (Suppl) 1-74.
11. Williams DE. Mycobacterium bovis BCG infection in humans. In: Thoen CO, Steele JH, editors. Mycobacterium bovis infection in animals and humans. Ames, IA: University Press; 1995. p. 47-61.
12. Brandt L., Feino Cunha J., Weinreich Olsen A.et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70:2002;672-678.
13. Orme I.M., McMurray D.N., Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol. 9:2001;115-118.
14. Morris S., Kelley C., Howard A., Li Z., Collins F. The immunogenicity of single and combination DNA vaccines against tuberculosis. Vaccine. 18:2000;2155-2163.
15. Collins D.M. New tuberculosis vaccines based on attenuated strains of the Mycobacterium tuberculosis complex. Immunol. Cell Biol. 78:2000;342-348.
16. Bloch H., Segal W. Viability and multiplication of vaccines in immunization against tuberculosis. Am. Rev. Tuberc. Pulm. Dis. 71:1955;228-248.
17. Youmans GP. Acquired immunity in tuberculosis. In: Youmans GP, editor. Tuberculosis. London: Saunders; 1979. p. 225-35.
18. Orme I.M. Induction of nonspecific acquired resistance and delayed-type hypersensitivity, but not specific acquired resistance in mice inoculated with killed mycobacterial vaccines. Infect. Immun. 56:1988;3310-3312.
19. Abou-Zeid C., Gares M.P., Inwald J.et al. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae. Infect. Immun. 65:1997;1856-1862.
20. Andersen P., Askgaard D., Ljungqvist L., Bentzon M.W., Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect. Immun. 59:1991;1558-1563.
21. Wiker H.G., Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Rev. 56:1992;648-661.
22. Lauvau G., Vijh S., Kong P.et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science. 294:2001;1735-1739.
23. Spahlinger H. Note on the treatment of tuberculosis. Lancet. 1:1922;5-8.
24. Paterson J.C., Crombie D.W., Coles J.C. Protection by killed vole bacillus vaccine against experimental tuberculosis in guinea pigs. Can. J. Res. 27:1949;37-42.
25. Singh I.G., Mukherjee R., Talwar G.P. Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine. 9:1991;10-14.
26. Anacker R.L., Barclay W.R., Brehmer W.et al. Effectiveness of cell walls of Mycobacterium bovis strain BCG administered by various routes and in different adjuvants in protecting mice against airborne infection with Mycobacterium tuberculosis strain H37Rv. Am. Rev. Respir. Dis. 99:1969;242-248.
27. Lowrie D.B., Tascon R.E., Silva C.L. Vaccination against tuberculosis. Int. Arch. Allergy Immunol. 108:1995;309-312.
28. Dubos R.J., Schaefer W.B., Pierce C.H. Antituberculous immunity in mice vaccinated with killed tubercle bacilli. J. Exp. Med. 97:1953;221-233.
29. Carabias E., Palenque E., Serrano R., Aguado J.M., Ballestin C. Evaluation of an immunohistochemical test with polyclonal antibodies raised against mycobacteria used in formalin-fixed tissue compared with mycobacterial specific culture. APMIS. 106:1998;385-388.
30. Gupta R.K., Varanelli C.L., Griffin P., Wallach D.F.H., Siber G.R. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens. Vaccine. 14:1996;219-225.
31. Zimmerman D.H., Ulrich J.T., Wright C., Lloyd J.P., Winship M.D., Sarin P.S. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17. AIDS Res. Hum. Retrovir. 14:1998;741-749.
32. Jacobs W.R. Jr., Kalpana G.V., Cirillo J.D.et al. Genetic systems for mycobacteria. Methods Enzymol. 204:1991;537-555.
33. Williams A., McBride B.W., Hall G., Fitzgeorge R.B., Farrar G.H. Experimental Legionnaires' disease in SCID-Beige mice reconstituted with human leucocytes. J. Med. Microbiol. 42:1995;433-441.
34. Chambers M.A., Williams A., Gavier-Widen D.et al. A guinea pig model of low-dose Mycobacterium bovis aerogenic infection. Vet. Microbiol. 80:2001;213-226.
35. Richards R.L., Hayre M.D., Hockmeyer W.T., Alving C.R. Liposomes, lipid A and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect. Immun. 56:1988;682-686.
36. Alving C.R., Verma J.N., Rao M.et al. Liposomes containing lipid A as a potent non-toxic adjuvant. Res. Immunol. 143:1992;197-198.
37. Baldwin S.L., D'Souza C., Roberts A.D.et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect. Immun. 66:1998;2951-2959.
38. Brandt L., Elhay M., Rosenkrands I., Lindblad E.B., Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect. Immun. 68:2000;791-795.
39. Wedlock D.N., Vesosky B., Skinner M.A., De Lisle G.W., Orme I.M., Buddle B.M. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 for protection against bovine tuberculosis. Infect. Immun. 68:2000;5809-5815.
40. Heilbron IM, Owens WM. The unsaponifiable matter from the oils of elasmobranch fish. Part IV. The establishment of the structure of selachyl and batyl alcohols as monoglyceryl ethers. J Chem Soc 1928;942-7.
41. Yamamoto N., St Claire D.A.J., Homma S., Ngwenya B.Z. Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res. 48:1988;6044-6049.
42. Chambers M.A., Williams A., Gavier-Widen D.et al. Identification of a Mycobacterium bovis BCG auxotrophic mutant that protects guinea pigs against M. bovis and hematogenous spread of Mycobacterium tuberculosis without sensitization to tuberculin. Infect. Immun. 68:2000;7094-7099.
43. Chambers M.A., Williams A., Hatch G.et al. Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. Infect. Immun. 70:2002;2159-2165.
44. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 69:2001;2773-2778.
45. Ginsberg A.M. What's new in tuberculosis vaccines? Bull. World Health Organ. 80:2002;483-488.
46. Olson B.J., Habel K., Piggott W.R. A comparative study of live and killed vaccines in experimental tuberculosis. Public Health Rep. 62:1947;293-296.
47. Sarber R.W., Nungester W.J., Stimpert F.D. Immunization studies with irradiated tuberculosis vaccines. Am. Rev. Tuberc. 62:1950;418-427.
48. Milzer A., Levinson S.O., Lewis M.B. Immunization of mice with ultraviolet killed tuberculosis vaccines. Proc. Soc. Exp. Biol. Med. 75:1950;733-736.
49. Seagle J.B., Karlson A.G., Feldman W.H. Irradiated antituberculosis vaccine, including comparison with BCG in experimentally infected guinea pigs. Am. Rev. Tuberc. 67:1952;341-353.
50. Izzo A.A., North R.J. Evidence for an alpha/beta T cell-independent mechanism of resistance to mycobacteria. Bacillus-Calmette-Guerin causes progressive infection in severe combined immunodeficient mice, but not in nude mice or in mice depleted of CD4+ and CD8+ T cells. J. Exp. Med. 176:1992;581-586.
51. Fidler I.J., Schroit A.J. Macrophage recognition of self from nonself: implications for the interaction of macrophages with neoplastic cells. Symp. Fundam. Cancer Res. 38:1986;183-207.
52. Freudenstein H., Weinmann E., Hill I. Potency testing of BCG vaccines on white mice: influence of variables on survival time, lung findings and vaccine assessment. Vaccine. 6:1988;315-327.
53. Rook GAW, Bloom BR. Mechanisms of pathogenesis in tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology; 1994. p. 485-501.
54. Wayne L.G., Sramek H.A. Antigenic differences between extracts of actively replicating and synchronized resting cells of Mycobacterium tuberculosis. Infect. Immun. 24:1979;363-370.
55. Andersen P., Askgaard D., Ljungqvist L., Bennedsen J., Heron I. Proteins released from Mycobacterium tuberculosis during growth. Infect. Immun. 59:1991;1905-1910.
56. James B.W., Williams A., Marsh P.D. The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium. J. Appl. Microbiol. 88:2000;669-677.
57. Dietrich G., Mollenkopf H.J., Weber H.et al. Cultivation of Mycobacterium bovis BCG in bioreactors. J. Biotechnol. 96:2002;259-570.